SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76391.39
363.66 (-0.47%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
61	Blue Jet Healthcare Ltd.	Q V PT	11,069 Small Cap	577.20 (-1.30%)	44.67	5.12	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
62	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,620 Small Cap	4,646.10 (0.75%)	41.18	23.5	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
63	Jupiter Life Line Hospitals Ltd.	Q V PT	10,245 Small Cap	1,576.30 (0.88%)	53.53	6.37	21.03	54.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
64	Healthcare Global Enterprises Ltd.	Q V+ PT	10,018 Small Cap	669.30 (-0.25%)	687.12	6.24	13.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
65	Strides Pharma Science Ltd.	Q V+ PT	9,591 Small Cap	1,030.60 (-0.95%)	52.23	2.92	4.81	-16.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
66	Suven Life Sciences Ltd.	Q V+ PT	9,018 Small Cap	316.95 (-0.69%)	N/A	5.14	-14.30	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
67	Thyrocare Technologies Ltd.	Q V+ PT	8,888 Small Cap	545.55 (-2.30%)	54.39	15.36	10.88	8.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
68	Yatharth Hospital & Trauma Care Services Ltd.	Q V PT	8,207 Small Cap	840.75 (-1.29%)	86.01	5.07	27.90	137.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
69	Sanofi India Ltd.	Q V PT	7,838 Small Cap	3,395.05 (-0.25%)	25.3	10.05	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
70	Sun Pharma Advanced Research Company Ltd.	Q V+ PT	6,943 Small Cap	214.25 (0.14%)	4.47	5.21	49.34	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
71	Nephrocare Health Services Ltd.	Q V+ PT	6,773 Small Cap	678.05 (0.68%)	N/A	7.11	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
72	Supriya Lifescience Ltd.	Q V+ PT	6,764 Small Cap	832.55 (-0.94%)	32.35	5.65	17.45	18.30	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
73	FDC Ltd.	Q V PT	6,672 Small Cap	401.65 (-1.99%)	23.33	2.68	9.23	1.32	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
74	Senores Pharmaceuticals Ltd.	Q V+ PT	6,421 Small Cap	1,395.65 (0.10%)	317.09	8.56	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
75	Kovai Medical Center & Hospital Ltd.	Q V PT	6,290 Small Cap	5,764.05 (0.27%)	25.73	4.77	14.01	17.17	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
76	Aarti Pharmalabs Ltd.	Q V+ PT	6,106 Small Cap	659.70 (-2.03%)	34.65	3.08	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
77	Innova Captab Ltd.	Q V PT	5,577 Small Cap	967 (-0.78%)	66.64	6.29	25.90	14.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
78	Bliss GVS Pharma Ltd.	Q V+ PT	4,761 Small Cap	462.85 (3.28%)	49.15	4.16	9.41	4.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
79	Orchid Pharma Ltd.	Q V PT	5,079 Small Cap	963 (-3.84%)	112.35	3.71	13.89	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
80	RPG Life Sciences Ltd.	Q V+ PT	4,971 Small Cap	2,902.35 (-3.43%)	43.16	8.21	12.70	21.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
81	IOL Chemicals And Pharmaceuticals Ltd.	Q V+ PT	4,349 Small Cap	147.25 (-0.61%)	31.59	2.42	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
82	Artemis Medicare Services Ltd.	Q V+ PT	4,332 Small Cap	271.85 (-0.66%)	41.88	4.98	21.41	79.02	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
83	Novartis India Ltd.	Q V+ PT	4,195 Small Cap	1,668.95 (-1.77%)	45.02	5.13	-4.06	54.56	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
84	Gujarat Themis Biosyn Ltd.	Q V+ PT	3,833 Small Cap	355.30 (1.01%)	82.11	13.32	12.12	15.55	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
85	Gufic Biosciences Ltd.	Q V PT	3,873 Small Cap	377 (-2.39%)	61.34	5.83	16.69	24.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
86	Unichem Laboratories Ltd.	Q V PT	3,716 Small Cap	530.65 (0.54%)	23.38	1.42	4.67	-173.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
87	Aarti Drugs Ltd.	Q V PT	3,765 Small Cap	408.90 (-0.88%)	19.32	2.43	5.74	4.42	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
88	SMS Pharmaceuticals Ltd.	Q V+ PT	3,631 Small Cap	384.95 (-0.72%)	41.45	4.51	13.70	14.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
89	Advanced Enzyme Technologies Ltd.	Q V PT	3,504 Small Cap	314.75 (0.58%)	26.59	5	9.82	13.51	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
90	Indraprastha Medical Corporation Ltd.	Q V+ PT	3,369 Small Cap	366.75 (-0.19%)	18.35	4.55	10.30	29.46	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Rubicon Research	1,531.10	4.52%
Bliss GVS Pharma	462.85	3.28%
Tarsons Products	315.85	2.70%
Marksans Pharma	246.50	2.32%
Piramal Pharma	180.85	2.15%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Acutaas Chemicals	3,455.90	-5.77%
Fermenta Biotech	401.95	-4.49%
Orchid Pharma	963	-3.84%
Cohance Lifesciences	422.40	-3.77%
Dishman Carbogen Amc	179.45	-3.70%

News about Top Pharma Companies in India

Jul, 2026

Sanofi India informs about analyst meet

Sanofi India has informed that the Company will hold an investor / analysts call for an update on Unaudited Financial Results for the quarter and half year ended 30th June 2026, the details enclosed.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Sanofi India informs about resignation of director

Pursuant to Regulation 30 of the Listing Regulations, Sanofi India has informed that Rachid Ayari (DIN:10408699) vide his letter dated 22nd July 2026, had conveyed his decision to step down from his current role as the Whole Time Director, Chief Financial Officer and Key Managerial Personnel of the Company with effect from the close of business hours on 30th September 2026, in view of his transition to another role within the Sanofi group. Accordingly, Rachid Ayari shall cease to be the Whole Time Director, Chief Financial Officer, Key Managerial Personnel and shall also cease to be Senior Management Personnel and member of the Risk Management Committee effective from the close of business hours on 30th September 2026. The Company places on record its sincere appreciation to Rachid Ayari for his valuable contributions, expert guidance, and dedicated assistance provided during his tenure with the Company. The Company is in the process of identifying a suitable candidate for the position of Chief Financial Officer, who will also be designated as a Key Managerial Personnel. The Company will inform the Stock Exchanges of the appointment in due course. The information required in terms of Regulation 30 read with Schedule III of the Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 is enclosed as ‘Annexure-I’ and letter received from Rachid Ayari is enclosed as ‘Annexure – II’.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Supriya Lifescience informs about newspaper advertisement

In terms of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Supriya Lifescience has informed that it enclosed copies of the newspaper advertisement extract for Postal Ballot Notice published in the newspapers, Financial Express (English Language) and Loksatta (Marathi Language).

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

SMS Pharmaceuticals informs about newspaper publication

Pursuant to Regulations 30 and 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, SMS Pharmaceuticals has enclosed copies of the newspaper advertisement published on 22nd July, 2026, informing the shareholders about transfer of shares to Investor Education Protection Fund (IEPF) pertaining to the unpaid/ unclaimed dividend for the financial year 2018 -2019. The advertisement has been published in the following newspapers: Financial Express (in English language), Nava Telangana (in Telugu language). The newspaper advertisements are also made available on the website of the Company www.smspharma.com at Investors Section.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

SMS Pharmaceuticals informs about disclosure

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SMS Pharmaceuticals has informed that a specimen of the reminder letter dispatched on 22th July, 2026 to the identified shareholders who have not claimed their dividends for seven or more consecutive years and whose shares are liable for transfer to the IEPF Authority, pursuant to Section 124(6) of the Companies Act, 2013 read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended from time to time, is being enclosed.

The above information is a part of company's filings submitted to BSE.

Jul, 2026

Gujarat Themis Biosyn informs about SAST disclosure

Gujarat Themis Biosyn has informed that it enclosed revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 20, 2026 for Themis Medicare.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Sun Pharmaceutical Industries Ltd.	4,66,179 Crore
2	Divis Laboratories Ltd.	1,96,095 Crore
3	Torrent Pharmaceuticals Ltd.	1,91,530 Crore
4	Apollo Hospitals Enterprise Ltd.	1,28,516 Crore
5	Cipla Ltd.	1,14,318 Crore
6	Zydus Lifesciences Ltd.	1,12,693 Crore
7	Lupin Ltd.	1,10,002 Crore
8	Mankind Pharma Ltd.	1,05,068 Crore
9	Max Healthcare Institute Ltd.	1,05,274 Crore
10	Dr. Reddys Laboratories Ltd.	98,742 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	28,735	61,408	39.57	12.93	27.13	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,066	1,91,530	88.53	22.78	45.95	29.04
Lupin Ltd. (M)	Somewhat Good	2,396	1,10,002	20.63	4.91	11.93	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,441	43,218	40.93	9.55	27.65	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,607	66,822	30.58	4.77	22.18	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,568	85,232	90.72
Sai Life Sciences Ltd. (S)	Very Good	1,240	26,541	51.95
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,066	1,91,530	42.54
Aurobindo Pharma Ltd. (M)	Very Good	1,524	88,203	36.43
Ajanta Pharma Ltd. (M)	Very Good	3,441	43,218	26.65
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,240	26,541	77.72	10.58	40.87	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,441	43,218	40.93	9.55	27.65	13.54
Mankind Pharma Ltd. (M)	Very Good	2,557	1,05,068	51.57	6.43	32.30	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,114	1,12,693	22.36	4.33	13.70	13.52
Lupin Ltd. (M)	Somewhat Good	2,396	1,10,002	20.63	4.91	11.93	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,396	1,10,002	20.63	4.91	11.93	32.37
Abbott India Ltd. (M)	Very Good	28,735	61,408	39.57	12.93	27.13	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,167	98,742	30.64	2.62	15.71	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,114	1,12,693	22.36	4.33	13.70	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,954	4,66,179	40.61	5.58	23.28	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Sanofi India informs about analyst meet

Sanofi India informs about resignation of director

Supriya Lifescience informs about newspaper advertisement

SMS Pharmaceuticals informs about newspaper publication

SMS Pharmaceuticals informs about disclosure

Gujarat Themis Biosyn informs about SAST disclosure

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.